Is Ritivel profitable in 2026?

No. Ritivel is pre-revenue as of mid-2026, a 3-person San Francisco startup that raised only about $500K in pre-seed funding via a convertible note around January 1, 2026, with no named paying customers disclosed as of July 2026.

Could AI replace Ritivel's own product?

Ironically yes. Ritivel itself sells AI drafting of regulatory documents, but Certara's CoAuthor shipped a competing GenAI drafting integration inside Veeva Vault RIM in October 2025, threatening to commoditize Ritivel's core 'AI-native drafting' pitch before it gains traction.

Who is Ritivel's biggest competitor?

Certara, whose CoAuthor GenAI regulatory-writing tool integrated with Veeva Vault RIM, the dominant life-sciences system of record, via the Veeva AI Partner Program announced October 21, 2025, directly overlapping Ritivel's core drafting use case.

Is Ritivel laying off staff?

There is no evidence of layoffs; Ritivel has held steady at 3 employees in San Francisco across YC directory snapshots from May through July 2026, and currently has no active job postings on YC's jobs platform.

Ritivel is a private, venture-backed startup founded in 2025 that went through Y Combinator's Winter 2026 batch, with Y Combinator listed as an investor in its roughly $500K pre-seed round dated around January 1, 2026.

Does Ritivel have any real customers yet?

As of July 2026, no named paying customers or contract values have been disclosed. The company cites 50+ conversations with pharma professionals during development, but this is a vendor-stated figure, not confirmed traction.

YC Winter 2026 · United States

Ritivel

ritivel.com ↗

AI-native platform for drafting FDA/EMA regulatory submissions like CSRs, CTDs, INDs, BLAs.

Losing its protection

Assessed 27 July 2026 · Evidence as of 27 July 2026

The structural protection is eroding.

On the recordSince 27 July 2026 · Checkable from Q1-Q2 2026 · Every call on the record Checkpoint: Expected seed round decision following YC W26 Demo Day

The call

A 3-person, pre-revenue team is chasing a niche that Veeva and Certara just filled inside the platform pharma already uses.

Ritivel uses artificial intelligence to help pharmaceutical companies draft regulatory documents faster and more accurately, cutting what normally takes weeks down to days. The problem is that Veeva, the company that already owns the main software that pharma companies use to manage these documents, just partnered with Certara to add AI drafting directly into their system, which removes Ritivel's main selling point and locks Ritivel out since it sits on top of Veeva rather than inside it. Ritivel also has no announced paying customers yet despite talking to 50+ companies, and other startups are building similar tools, so the company needs to prove it can actually convert conversations into real revenue and customers before the gap between what it offers and what Veeva plus Certara offer grows too wide to close.

Why

AI pressure: Certara CoAuthor (GenAI regulatory-writing tool). CoAuthor already drafts submissions inside Veeva Vault RIM, matching the speed claim Ritivel built its pitch on. Could AI do the core job? Yes, likely.

Bigger players: Veeva Systems (Vault RIM platform). Veeva owns the system of record most pharma already runs on and now hosts Certara's AI drafting tool through its partner program. Could a giant copy it? Yes, easily.

What protects it. On-premise, no-cloud-storage deployment claim, though this is unverified and easy for larger vendors to copy.

What would change this call

Ritivel discloses a named paying pharma or biotech customer within 12 months. Would show it can convert conversations into real revenue, not just pilots.
Certara or Veeva announces expanded CoAuthor features matching Ritivel's CTD/CSR drafting claims. Would show the incumbent is closing the feature gap Ritivel relies on.
Ritivel's headcount stays at 3 through mid-2026 with no seed round announced. Would indicate stalled traction and difficulty raising beyond YC pre-seed.

Key numbers

3 employees, San Francisco (2026-07-07)
$500K raised across two rounds (2025-12-31)
50+ pharma conversations, zero named customers (2026-01-30)

Named risks

Pre-revenue with only $500K raised and 3-person team facing well-funded incumbents. Severity: high
Core drafting feature already replicated inside Veeva Vault RIM via Certara integration. Severity: high
No named customers or contract revenue disclosed as of mid-2026. Severity: high
Crowded niche with multiple identically-scoped AI-native startups (SyncIQ, Weave Bio, Peer AI). Severity: medium
No owned data layer or platform lock-in, sits atop Veeva's ecosystem rather than controlling it. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Certara (CoAuthor) / Veeva Systems	losing to	Certara CoAuthor shipped integrated with Veeva Vault RIM Oct 21, 2025, ahead of Ritivel's Jan 2026 launch
DDi (REGai)	contesting	REGai adds agentic AI to regulatory ops and covers medical-device pathways Ritivel does not, as of Jul 2026
SyncIQ	contesting	Named as AI-native regulatory-writing peer targeting same niche as of Jul 2026
Weave Bio	contesting	Named as AI-native CMC-authoring startup competing in same space as of Jul 2026
Peer AI	contesting	Named as comparable AI-native regulatory-writing startup as of Jul 2026
LORENZ / EXTEDO	contesting	Legacy eCTD publishing vendors favored by mid-to-large sponsors as of May 2026

Questions people ask

Is Ritivel profitable in 2026?: No. Ritivel is pre-revenue as of mid-2026, a 3-person San Francisco startup that raised only about $500K in pre-seed funding via a convertible note around January 1, 2026, with no named paying customers disclosed as of July 2026.
Could AI replace Ritivel's own product?: Ironically yes. Ritivel itself sells AI drafting of regulatory documents, but Certara's CoAuthor shipped a competing GenAI drafting integration inside Veeva Vault RIM in October 2025, threatening to commoditize Ritivel's core 'AI-native drafting' pitch before it gains traction.
Who is Ritivel's biggest competitor?: Certara, whose CoAuthor GenAI regulatory-writing tool integrated with Veeva Vault RIM, the dominant life-sciences system of record, via the Veeva AI Partner Program announced October 21, 2025, directly overlapping Ritivel's core drafting use case.
Is Ritivel laying off staff?: There is no evidence of layoffs; Ritivel has held steady at 3 employees in San Francisco across YC directory snapshots from May through July 2026, and currently has no active job postings on YC's jobs platform.
Who owns Ritivel?: Ritivel is a private, venture-backed startup founded in 2025 that went through Y Combinator's Winter 2026 batch, with Y Combinator listed as an investor in its roughly $500K pre-seed round dated around January 1, 2026.
Does Ritivel have any real customers yet?: As of July 2026, no named paying customers or contract values have been disclosed. The company cites 50+ conversations with pharma professionals during development, but this is a vendor-stated figure, not confirmed traction.

Timeline

2026-02-08Fondo covers Ritivel's public launch as AI-native regulatory document platform
2026-01-30Ritivel publicly launches via Y Combinator's Launch YC program
2026-01-01Ritivel closes convertible note as part of ~$500K pre-seed round
2025-10-21Certara CoAuthor integrates with Veeva Vault RIM via Veeva AI Partner Program
2025Ritivel founded in San Francisco

Revision history

27 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

CellType OctaPulse The Token Company